A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Tazarotene/ulobetasol (Primary) ; Ulobetasol (Primary) ; Tazarotene; Ulobetasol
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 New trial record